Enalapril

Generic Name: Enalapril

Brand Names: Epaned, Vaseretic, Vasotec, Aqumeldi

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅

CAS Number: 75847-73-3

Unique Ingredient Identifier: 69PN84IO1A

Background: Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-a...

Indication: Indicated for the management of essential or renovascular hypertension as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.

Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.
...

Associated Conditions: Diabetic Nephropathy, Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left ventricular dysfunction

Associated Therapies: -

Clinical Trials

Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children

Not Applicable

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Enalapril

First Posted Date: 2010-03-30

Last Posted Date: 2012-07-26

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 5

Registration Number: NCT01096121

Locations: 🇫🇷
Trousseau Hospital, Nephro-pediatric unit, Paris, France

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Lercanidipine + Enalapril
Drug: Placebo
Drug: Lercanidipine
Drug: Enalapril

First Posted Date: 2010-03-26

Last Posted Date: 2011-04-29

Lead Sponsor: RECORDATI GROUP

Target Recruit Count: 1039

Registration Number: NCT01093807

Locations: 🇫🇷
Hôpital de la Pitié-Salpétrière, Paris, France

Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human

Phase 4

Conditions: Heart Failure

Interventions: Drug: Enalapril

First Posted Date: 2010-02-17

Last Posted Date: 2010-02-25

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 60

Registration Number: NCT01069042

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

Phase 4

Conditions: Continuous Ambulatory Peritoneal Dialysis

Interventions: Drug: Enalapril plus Losartan
Drug: Placebo
Drug: Enalapril

First Posted Date: 2010-01-05

Last Posted Date: 2010-05-12

Lead Sponsor: Chulalongkorn University

Target Recruit Count: 90

Registration Number: NCT01041963

Locations: 🇹🇭
Chulalongkorn university, Bangkok, Thailand

Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia

Phase 1

Conditions: Diabetic Macular Ischemia

Interventions: Drug: placebo
Other: oxygen
Drug: enalapril

First Posted Date: 2009-05-12

Last Posted Date: 2009-05-12

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Registration Number: NCT00899587

Locations: 🇮🇷
Ophthalmic Research Center, Tehran, Iran, Islamic Republic of

Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: enalapril maleate

First Posted Date: 2009-05-08

Last Posted Date: 2019-05-08

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 19

Registration Number: NCT00895414

Locations: 🇺🇸
Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸
University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States

A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: losartan potassium
Drug: Enalapril
Drug: Placebo

First Posted Date: 2009-04-16

Last Posted Date: 2015-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 576

Registration Number: NCT00882440

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

Phase 3

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: Enalapril
Drug: Aliskiren

First Posted Date: 2009-03-02

Last Posted Date: 2016-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7064

Registration Number: NCT00853658

Locations: 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

China Stroke Primary Prevention Trial

Phase 4

Completed

Conditions: Primary Hypertension

Interventions: Drug: Enalapril/folic acid
Drug: Enalapril maleate

First Posted Date: 2008-11-20

Last Posted Date: 2014-08-12

Lead Sponsor: Shenzhen Ausa Pharmed Co.,Ltd

Target Recruit Count: 20702

Registration Number: NCT00794885

Locations: 🇨🇳
Lianyungang Center for Advanced Research in Cardiovascular Diseases, Lianyungang, Jiangsu, China
🇨🇳
Anqing Branch, Anhui Institute of Biomedical Research, Anqing City, Anhui, China

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.

Phase 4

Conditions: Atherosclerosis
Cardiovascular Diseases

Interventions: Drug: Simvastatin or Atorvastatin
Drug: Enalapril
Drug: Aspirin or clopidogrel
Drug: Rimonabant

First Posted Date: 2008-08-14

Last Posted Date: 2008-08-14

Lead Sponsor: Hospital Arnau de Vilanova

Target Recruit Count: 2948

Registration Number: NCT00734123

Locations: 🇪🇸
Hospital Arnau de Vilanova, Lleida, Catalunya, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy